Minerva Neurosciences (NERV) Change in Account Payables (2014 - 2026)
Minerva Neurosciences posted quarterly Change in Account Payables of $1.5 million for Q1 2026, up 251.37% year-on-year from $416964.4 in Q1 2025, and up 632.31% on a QoQ basis from -$275228.0 in Q4 2025.
Minerva Neurosciences (NERV) has 13 years of Change in Account Payables data on file, last reported at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 251.37% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 272.69% YoY), and the FY2025 full-year result was -$1.1 million, down 436.27% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.5 million, up from -$275228.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q1 2026 and bottomed at -$986841.0 in Q3 2022.
- The 5-year median for Change in Account Payables is -$72739.0 (2025), against an average of $9452.4.
- The widest annual swing landed in 2024, when Change in Account Payables plunged 4165.22%; it then soared 251.37% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $436779.0 in 2022, then retreated by 6.07% to $410250.0 in 2023, then soared by 157.08% to $1.1 million in 2024, then slumped by 126.1% to -$275228.0 in 2025, then jumped by 632.31% to $1.5 million in 2026.
- The last three Change in Account Payables figures came in at $1.5 million (Q1 2026), -$275228.0 (Q4 2025), and -$72739.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | -275,228.00 |
| Dec 31, 2025 | -275,228.00 |
| Sep 30, 2025 | -72,739.00 |
| Sep 30, 2025 | -72,739.00 |
| Jun 30, 2025 | 256,853.00 |
| Jun 30, 2025 | 256,853.00 |
| Mar 31, 2025 | -967,898.00 |
| Mar 31, 2025 | -967,898.00 |
| Dec 31, 2024 | 1.05 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | -275,153.00 |
| Sep 30, 2024 | -275,153.00 |
| Jun 30, 2024 | -607,223.00 |
| Jun 30, 2024 | -607,223.00 |
| Mar 31, 2024 | -369,752.00 |
| Mar 31, 2024 | -369,752.00 |
| Dec 31, 2023 | 410,250.00 |
| Dec 31, 2023 | 410,250.00 |
| Sep 30, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | -662,747.00 |
| Jun 30, 2023 | -662,747.00 |
| Mar 31, 2023 | -8,669.00 |
| Mar 31, 2023 | -8,669.00 |
| Dec 31, 2022 | 436,779.00 |
| Dec 31, 2022 | 436,779.00 |
| Sep 30, 2022 | -986,841.00 |
| Sep 30, 2022 | -986,841.00 |
| Jun 30, 2022 | -66,439.00 |
| Jun 30, 2022 | -66,439.00 |
| Mar 31, 2022 | -267,047.00 |
| Mar 31, 2022 | -267,047.00 |
| Dec 31, 2021 | 652,706.00 |
| Dec 31, 2021 | 652,706.00 |
| Sep 30, 2021 | -393,188.00 |
| Sep 30, 2021 | -393,188.00 |
| Jun 30, 2021 | 464,070.00 |
| Jun 30, 2021 | 464,070.00 |
| Mar 31, 2021 | 134,013.00 |
| Mar 31, 2021 | 134,013.00 |
| Dec 31, 2020 | 294,029.00 |
| Dec 31, 2020 | 294,029.00 |
| Sep 30, 2020 | -2.44 Mn |
| Sep 30, 2020 | -2.44 Mn |
| Jun 30, 2020 | 135,505.00 |
| Jun 30, 2020 | 135,505.00 |
| Mar 31, 2020 | 686,050.00 |
| Mar 31, 2020 | 686,050.00 |
| Dec 31, 2019 | -3.01 Mn |
| Dec 31, 2019 | -3.01 Mn |
| Sep 30, 2019 | 2.39 Mn |
| Sep 30, 2019 | 2.39 Mn |
| Jun 30, 2019 | -83,775.00 |
| Jun 30, 2019 | -83,775.00 |
| Mar 31, 2019 | 1.23 Mn |
| Mar 31, 2019 | 1.23 Mn |
| Dec 31, 2018 | 924,917.00 |
| Dec 31, 2018 | 924,917.00 |
| Sep 30, 2018 | -435,094.00 |
| Sep 30, 2018 | -435,094.00 |
| Jun 30, 2018 | -1.52 Mn |
| Jun 30, 2018 | -1.52 Mn |
| Mar 31, 2018 | 1.39 Mn |
| Mar 31, 2018 | 1.39 Mn |
| Dec 31, 2017 | -67,776.00 |
| Dec 31, 2017 | -67,776.00 |
| Sep 30, 2017 | 95,743.00 |
| Sep 30, 2017 | 95,743.00 |
| Jun 30, 2017 | -1.87 Mn |
| Jun 30, 2017 | -1.87 Mn |
| Mar 31, 2017 | 1.81 Mn |
| Mar 31, 2017 | 1.81 Mn |
| Dec 31, 2016 | 635,112.00 |
| Dec 31, 2016 | 635,112.00 |
| Sep 30, 2016 | 93,267.00 |
| Sep 30, 2016 | 93,267.00 |
| Jun 30, 2016 | -483,997.00 |
| Jun 30, 2016 | -483,997.00 |
| Mar 31, 2016 | -136,610.00 |
| Mar 31, 2016 | -136,610.00 |
| Dec 31, 2015 | 625,771.00 |
| Dec 31, 2015 | 625,771.00 |
| Sep 30, 2015 | 170,509.00 |
| Sep 30, 2015 | 170,509.00 |
| Jun 30, 2015 | -332,053.00 |
| Jun 30, 2015 | -332,053.00 |
| Mar 31, 2015 | 254,529.00 |
| Mar 31, 2015 | 254,529.00 |
| Dec 31, 2014 | -290,165.00 |
| Dec 31, 2014 | -290,165.00 |
| Sep 30, 2014 | -570,500.00 |
| Sep 30, 2014 | -570,500.00 |
| Jun 30, 2014 | 42,211.00 |
| Jun 30, 2014 | 42,211.00 |
| Mar 31, 2014 | 1.19 Mn |
| Mar 31, 2014 | 1.19 Mn |